Certara Inc. CERT

Certara, Inc. offers biosimulation and technology-enabled services for drug discovery and development. It was founded in 2008 with its headquarters in Princeton, New Jersey. The company has customers across 61 countries and is regarded as the global leader in biosimulation.

Certara offers four main services for customers. First, integrated drug development allows the company to use pharmacology strategies for drug concepts and innovations. Second, regulatory science is used for submission and approvals with the help of artificial intelligence. Third, biosimulation and information provides a software service that shows the drug development life cycles and modelling. Lastly, the company's HOPE Bayesian modelling engine works to optimise decision analytics and modelling, value and access consulting, and real world data solutions. In 2021, Certara's Simcyp COVID-19 Vaccine Model won the R&D 100 award, which recognises the company as one of the top pioneers in the field of science and technology.

Certera has proposed more than 200 global regulatory and health authority submissions since 2017. Its End-to-End Platform shows its systematic approach to drug development with the aid of technology. With this approach, the company discovers drugs, conducts preclinical and clinical trials, and consults drugs for post-approval phases. Certera started trading on the NASDAQ in 2020 under the ticker CERT.

Follow CERT shares and stay up to date on its value changes here on eToro.